"What do people living with HIV need to know most about COVID-19?" Dr. David Wohl of the UNC CFAR's Clinical Core recently spoke with POSITIVELY … Read More
UNC Center for AIDS Research
It's about a real-life response to AIDS - a fierce commitment to creating and translating knowledge that advances the fight against HIV & AIDS
COVID-19 AND HIV Q&A WITH DR. DAVID WOHL – Positively Aware Magazine
IDWeek Featured Session: “All Policy Is Health Policy” with Dr. Ada Adimora
Join the other 12,000+ IDWeek attendees who enjoyed the powerful talk from Adaora Adimora, M.D., MPH, on “All Policy Is Health Policy: Pathways to HIV … Read More
Expecting the Unexpected: LEVERAGING HIV RESEARCH TO FIND A TREATMENT FOR COVID-19
Carolina experts are leveraging 40 years of HIV research to find a treatment for COVID-19. The Well recently published an article detailing UNC's … Read More
UNC CFAR in the News
NIH Re-Funds ACTG for the Next Seven Years
The AIDS Clinical Trials Group (ACTG) Network has been re-funded for the next seven years by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The ACTG is the largest global HIV research network. Dr. Joe Eron, UNC CFAR Clinical Core Director, is vice chair of the… Read More
ACTG honors David Wohl, MD, with first Charles van der Horst Humanitarian Award
ACTG names second new award for former UNC neurology professor, Kevin Robertson. “The national AIDS Clinical Trials Group expanded its annual recognition program in 2020 with two new awards named for University of North Carolina faculty members who died in 2019: Charles van der Horst, MD, an infectious diseases physician and researcher, and Kevin Robertson,… Read More
CFAR Directors recognized in 2020 Global Highly Cited Researchers List
“Twenty-one UNC School of Medicine and 16 other UNC-Chapel Hill researchers have been named in Clarivate’s 2020 list of Highly Cited Researchers™, scientific pioneers from around the world whose names are drawn from the publications that rank in the top 1% by citations for field and publication year in the Web of Science™ citation index.”… Read More
‘Major advance’: Long-acting injectable more effective than daily pill in preventing HIV
“A long-acting injectable drug, cabotegravir, is safe and more effective than a daily pill in preventing HIV acquisition, according to results from a study of 3,127 cisgender women in sub-Saharan Africa. Led by UNC researchers beginning in November 2017, the study showed such promising results that a review board recommended ending the blinded phase of… Read More
